F M Investments LLC Buys 550 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

F M Investments LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,003 shares of the biopharmaceutical company's stock after acquiring an additional 550 shares during the quarter. F M Investments LLC's holdings in Regeneron Pharmaceuticals were worth $4,988,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pamalican Asset Management Ltd acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $4,915,000. Intact Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $356,000. Principal Financial Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after buying an additional 2,828 shares in the last quarter. Rhenman & Partners Asset Management AB lifted its position in shares of Regeneron Pharmaceuticals by 11.4% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after buying an additional 4,457 shares during the last quarter. Finally, Fagan Associates Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock valued at $9,205,000 after purchasing an additional 3,832 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on REGN shares. Citigroup cut their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. The Goldman Sachs Group dropped their price objective on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating on the stock in a research note on Monday. Sanford C. Bernstein decreased their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 4th. Finally, Bernstein Bank cut their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $964.88.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded down $5.96 during trading on Wednesday, reaching $551.95. The company's stock had a trading volume of 307,660 shares, compared to its average volume of 707,860. The firm has a market cap of $60.34 billion, a price-to-earnings ratio of 14.42, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20. The business's fifty day moving average price is $653.75 and its 200-day moving average price is $748.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $11.86 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.